NSE: TATVA | BSE: 543321

Expensive Performer

Download real time

953.80 -2.15 (-0.22%)

53.59% Gain from 52W Low

43,547 NSE+BSE Volume

NSE 11 Jun, 2025 3:31 PM (IST)

2,231.1

Market Cap

Below industry Median

0.7

Beta 1Year

Very Low volatility

Tatva Chintan Pharma Chem Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TATVA, BSE:543321 Tatva Chintan Pharma Chem Ltd.

Search Inside the pdf :

Tatva Chintan Pharma Chem Ltd.

07 May 2025

953.80

-0.22%

Lackluster Performance overshadows positive management Outlook

Hold: Tatva Chintan Pharma Chem ...

Recommendation Target

KRChoksey

Tatva Chintan Pharma Chem’s Q4FY25 revenue stood at INR 1,079 Mn., up by 9.8% YoY (+25.6% QoQ), above our estimates by 4.3%, led by strong double-digit growth in PTC and PASC segments. EBITDA came in at INR 90 Mn., down by 42.7% YoY (+26.8% QoQ), below our estimates driven by lower-than-expected gross margins.

Tatva Chintan Pharma.. has an average target of 883.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

06 May 2025

953.80

-0.22%

TATVA remain hopeful for strong recovery in FY26

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.

Tatva Chintan Pharma Chem Ltd. has gained 36.30% in the last 3 Months

Tatva Chintan Pharma Chem Ltd.

30 Jan 2025

953.80

-0.22%

Outlook remains uncertain with lack of visibility in the key SDA segment

Sell: Tatva Chintan Pharma Chem ...

Target

KRChoksey

TATVA revenue missed our estimates due to significant decline in SDA segment. EBITDA beat our estimates due to lower-than-expected cost of goods sold and operating expenses. However, Adj PAT missed our estimates significantly due to higher-than-expected depreciation, lower than expected other income.

Tatva Chintan Pharma Chem Ltd. has gained 36.30% in the last 3 Months

Tatva Chintan Pharma Chem Ltd.

28 Oct 2024

953.80

-0.22%

Multiple headwinds across demand and supply sides persist

Sell: Tatva Chintan Pharma Chem ...

Recommendation Target

KRChoksey

Tatva Chintan Pharma Chem’s revenue and profitability missed our estimates significantly due to muted demand across business segments, lower price realization, and an increase in fixed costs.
We believe short term pain will persist as Q3FY25E is expected to have similar performance; However, mid-term may improve gradually with a pick-up in global demand and commercialization of new products.

Tatva Chintan Pharma.. has an average target of 883.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

30 Jul 2024

953.80

-0.22%

Fall in price realization impacted topline and profitability

Hold: Tatva Chintan Pharma Chem ...

Target

KRChoksey

Tatva Chintan Pharma Chem’s revenue missed our estimates (-32.7%) due to a steep decline in price realization. EBITDA missed our estimate (-58.1%) due to better-than-expected operating expenses.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

25 Jul 2024

953.80

-0.22%

Margins impacted by high-cost inventory

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.

Tatva Chintan Pharma Chem Ltd. has gained 29.13% in the last 1 Month

Tatva Chintan Pharma Chem Ltd.

09 May 2024

953.80

-0.22%

Steep fall in price realization impacted topline growth

Hold: Tatva Chintan Pharma Chem ...

Target

KRChoksey

Tatva Chintan Pharma Chem missed our revenue estimate slightly due to decline in growth across business segments. However, EBITDA beat our estimate due to lower-than-expected employee expenses and lower than expected cost of goods sold.

Tatva Chintan Pharma.. has an average target of 883.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

24 Jan 2024

953.80

-0.22%

Sharp decline in revenue and profitability as weak demand continue

Accumulate: Tatva Chintan Pharma Chem ...

Target

KRChoksey

For Q3FY24, TATVA revenue was INR 842 Mn which declined by 30.2% YoY and 12.9% QoQ. This significant decline was due to continued subdued demand for the specialty chemical industry and financial year-end for global end customers.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

21 Nov 2023

953.80

-0.22%

Reasonable revenue growth with significant improvement in profitability

Accumulate: Tatva Chintan Pharma Chem ...

Recommendation Target

KRChoksey

For Q2FY24, Tatva Chintan Pharma Chem’s revenue grew 7.3% YoY but declined 15.5% QoQ to INR 967 Mn. This is mainly driven by robust growth in the SDA segment (44.0% of revenue), a growth of 487.0% YoY to INR 428 Mn due to steady improvement in commercial vehicle sales, and the addition of new customers.

Tatva Chintan Pharma.. has an average target of 883.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

27 Sep 2023

953.80

-0.22%

Core business normalising; new products pipeline maturing

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

VOTE: Is Tatva Chintan Pharma Chem Ltd. worth buying?

48 Votes:

Buy 58.33%

Sell 22.92%

Hold 18.75%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf